 |
 |
July 27th, 2005
New generation treatment option for von Willebrand disease (VWD) to be presented a the upcoming ISTH congress 2005 in Sydney, Australia
Wilate®, a new generation, double-virus inactivated VWF/FVIII-concentrate, developed for the treatment of VWD, will be presented to an international audience for the first time in a breakfast symposium at the upcoming XXth Congress of the International Society on Thrombosis and Haemostasis in Sydney Australia, August 6-12. The ISTH congress, the largest congress in the field of thrombosis and haemostasis in the world, presents an excellent opportunity to introduce Wilate to the international community of treatment providers and researchers in the area of VWD, in anticipation for the completion of MRP approval in Europe and applications for registration in the USA and Austrailia.
|
 |
Octapharma, a bronze sponsor of the ISTH congress, will also participate in the exhibition with a 108sqm booth which will highlight Wilate along with our entire coagulation product line. Join us at booth # 429 to learn more about Wilate, participate in the Wilate quiz challenge, and enjoy refreshments in our Oasis themed booth. From Aug 10, a video of the breakfast symposium will be available on CD from the Octapharma booth.
Octapharma Breakfast Symposium
Tuesday, Aug 9, 2005 - Ballroom 1
Breakfast at 6:30 am
Symposium from 7:00 -8:15 am
This symposium has been approved by the American Medical Association for AMA PRA Category 1 Credit.
|
Actual Improvements in the Treatment of VWD: Wilate - Double Virus
Inactivation, Optimized Pharmacokinetics and Convenience for VWD
patient.
|
| 06:30 |
Breakfast in the foyer outside ballroom 1 |
| 07:00 |
Chairman: Prof. Ian Peake, Sheffield, UK
Welcome and introduction
|
| 07:03 |
Tor Einar-Svae, Octapharma, Vienna, Austria
Characterisation of a new generation, high-purity, double-virus-inactivated VWF/FVIII-concentrate - Wilate |
| 07:23 |
Craig M. Kessler, MD,
Georgetown
Univ
.
Hosp.
Washington
D
C, USA
Pharmacokinetic properties of Wilate in Subjects with inherited von Willebrand disease |
| 07:35 |
Erik Berntorp, Lund University, Malmö University Hospital, Sweden
The use of Wilate in the treatment of acute bleeding episodes and prophylaxis - recent results from a prospective multicenter study |
| 07:55 |
Jerzy Windyga, Phd, MD, Inst. Of Hematology and Blood Transfusion, Warsaw, Poland
Clinical efficacy and safety of wilate in elective and urgent surgical proceudres |
| 08:07 |
Prof. Ian Peake
Panel Discussion |
| 08:13 |
Prof. Ian Peake
Summary and Closing Remarks |
| 08:15 |
Closing |
|
We look forward to seeing you down under!
© Octapharma AG, 2005 |
